Predictive role of free prostate-specific antigen in a prospective active surveillance program (PRIAS)

World Journal of Urology

Volumn 33, Issue 11, 2015, Pages 1735-1740

  Vasarainen, Hanna ^a   Salman, Jolanda ^b   Salminen, Heidi ^a   Valdagni, Riccardo ^c   Pickles, Tom ^d   Bangma, Chris ^b   Roobol, Monique J ^b   Rannikko, Antti ^a  

^a PEIJAS HOSPITAL   (Finland)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Active surveillance; Free prostate specific antigen; Prostate cancer; Prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

AGED; BIOPSY; BLOOD; CANCER STAGING; CLINICAL TRIAL; EARLY CANCER DIAGNOSIS; FOLLOW UP; HEALTH; HUMAN; INCIDENCE; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; PROSPECTIVE STUDY; PROSTATIC NEOPLASMS; SURVIVAL RATE; TIME FACTOR; TRENDS;

AGED; BIOMARKERS, TUMOR; BIOPSY; EARLY DETECTION OF CANCER; FOLLOW-UP STUDIES; GLOBAL HEALTH; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL RATE; TIME FACTORS;

EID: 84945449082     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-015-1542-3     Document Type: Article

References (28)

1. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR (2007) Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol 178(3 Pt 2):S14–S19
2. Parker C (2004) Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncol 5(2):101–106
3. Bul M, Zhu X, Valdagni R et al (2013) Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol 63(4):597–603
4. Dall’Era MA, Konety BR, Cowan JE et al (2008) Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer 112(12):2664–2670
5. van As NJ, Norman AR, Thomas K et al (2008) Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. Eur Urol 54(6):1297–1305
6. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A (2010) Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28(1):126–131
7. Tosoian JJ, Trock BJ, Landis P et al (2011) Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 29(16):2185–2190
8. Ouzzane A, Puech P, Villers A (2012) MRI and surveillance. Curr Opin Urol 22(3):231–236
9. Stamatakis L, Siddiqui MM, Nix JW et al (2013) Accuracy of multiparametric magnetic resonance imaging in confirming eligibility for active surveillance for men with prostate cancer. Cancer 119(18):3359–3366
10. Isharwal S, Makarov DV, Sokoll LJ et al (2011) ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program. Urology 77(3):763.e1–763.e6
11. Catalona WJ, Smith DS, Wolfert RL et al (1995) Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 274(15):1214–1220
12. Partin AW, Catalona WJ, Southwick PC, Subong EN, Gasior GH, Chan DW (1996) Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. Urology 48(6A Suppl):55–61
13. Visapaa H, Hotakainen K, Lundin J, Ala-Opas M, Stenman UH (2010) The proportion of free PSA and upgrading of biopsy Gleason score after radical prostatectomy. Urol Int 84(4):378–381
14. Ramirez ML, Nelson EC, Deverewhite RW, Lara PN Jr, Evans CP (2008) Current applications for prostate-specific antigen doubling time. Eur Urol 54(2):291–300
15. van den Bergh RC, Roemeling S, Roobol MJ, Roobol W, Schroder FH, Bangma CH (2007) Prospective validation of active surveillance in prostate cancer: the PRIAS study. Eur Urol 52(6):1560–1563
16. Southwick PC, Catalona WJ, Partin AW et al (1999) Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial. J Urol 162(4):1346–1351
17. Catalona WJ, Southwick PC, Slawin KM et al (2000) Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology 56(2):255–260
18. Nam RK, Toi A, Klotz LH et al (2007) Assessing individual risk for prostate cancer. J Clin Oncol 25(24):3582–3588
19. Selvadurai ED, Singhera M, Thomas K et al (2013) Medium-term outcomes of active surveillance for localised prostate cancer. Eur Urol 64(6):981–987
20. San Francisco IF, Werner L, Regan MM, Garnick MB, Bubley G, DeWolf WC (2011) Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance. J Urol 185(2):471–476
21. Kotb AF, Tanguay S, Luz MA, Kassouf W, Aprikian AG (2011) Relationship between initial PSA density with future PSA kinetics and repeat biopsies in men with prostate cancer on active surveillance. Prostate Cancer Prostatic Dis 14(1):53–57
22. Iremashvili V, Manoharan M, Lokeshwar SD, Rosenberg DL, Pan D, Soloway MS (2013) Comprehensive analysis of post-diagnostic prostate-specific antigen kinetics as predictor of a prostate cancer progression in active surveillance patients. BJU Int 111(3):396–403
23. Ng MK, Van As N, Thomas K et al (2009) Prostate-specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity versus PSA doubling time. BJU Int 103(7):872–876
24. Patel HD, Feng Z, Landis P, Trock BJ, Epstein JI, Carter HB (2013) Prostate specific antigen velocity risk count predicts biopsy reclassification for men with very low risk prostate cancer. J Urol 191(3):629–637
25. Vellekoop A, Loeb S, Folkvaljon Y, Stattin P (2014) Population based study of predictors of adverse pathology among candidates for active surveillance with gleason 6 prostate cancer. J Urol 191(2):350–357
26. Steuber T, Vickers AJ, Serio AM et al (2007) Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer. Clin Chem 53(2):233–240
27. Southwick PC, Catalona WJ, Partin AW et al (1999) Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial. J Urol 162(4):1346–1351
28. Elabbady AA, Khedr MM (2006) Free/total PSA ratio can help in the prediction of high gleason score prostate cancer in men with total serum prostate specific antigen (PSA) of 3–10 ng/ml. Int Urol Nephrol 38(3–4):553–557